Summary: The role of tumor necrosis factor-alpha (TNF-a) in brain injury is controversial. We studied the effect of anti TNF-a antibody in a rat model of reversible middle cerebral artery occlusion. During focal ischemia and early reperfusion, TNF-a was rapidly and transiently released into circulation.
The role of tumor necrosis factor-alpha (TNF-a) in brain injury is controversial. It has been shown that TNF-a under in vitro conditions may protect neurons against metabolic-excitotoxic insults and cytotoxic ef fects of amyloid-!3 peptide and iron by promoting main tenance of intracellular calcium homeostasis and by sup pressing the accumulation of reactive oxygen species (Cheng et aI., 1994; Barger et aI., 1995) . The "neuro protective" theory has been supported by findings that damage to neurons caused by focal cerebral ischemia and epileptic seizures was exacerbated in TNFR-KO mice, which are genetically deficient in TNF receptors (Bruce et aI., 1996) . An increase in reactive oxygen species in response to excitotoxic stimuli and reduced levels of manganese superoxide dismutase in TNFR-KO mice led to the concept that TNF-a may protect neurons by stimu lating antioxidant pathways (Bruce et aI. , 1996) .
On the other hand, a vast body of evidence indicates that TNF-a is a major deleterious cytokine in stroke and traumatic brain injury. It is known that TNF-a is ex pressed in ischemic brain (Liu et aI., 1994) , and immu nocytochemical studies confirm the presence of TNF-a injury, enhanced the cerebral blood flow during reperfusion, and improved the neurologic outcome. This further supports the contention that TNF-a is a deleterious cytokine in stroke, whereas circulating antibody against TNF-a may protect brain from reperfusion injury. Key Words: Tumor necrosis factor Neutralizing antibody-Focal ischemia-Cerebral protec tion-Rats.
antigen in brain as early as 30 minutes after occlusion of the middle cerebral artery (MCA) in the same regions where TNF-a mRNA-positive cells were detected (Buttini et aI., 1996) . Early increases in TNF-a levels after transient cerebral ischemia in gerbil brain also have been demonstrated (Saito et aI., 1996) . It has been re ported that intracerebroventricular administration of TNF-a increases the volume of brain injury after MCA occlusion in a dose-dependent fashion (Barone et aI., 1997) . Furthermore, topical application of the type I soluble TNF-a (TNFbp) receptor (Nawashiro et aI. , 1997) or anti-TNF-a antibody (Ab) (Meistrell et aI., 1997) resulted in amelioration of brain infarction in a model of permanent MCA occlusion, whereas intrave nous pretreatment with TNFbp reduced brain injury after permanent MCA occlusion in spontaneously hyperten sive rats (Dawson et aI. , 1996) . In a closed head injury, systemic administration of agents that block TNF-a syn thesis (e. g. , pentoxifyJline) or TNFbp was associated with cerebral protection (Shohami et aI., 1996) . Studies in transgenic mice demonstrate that overexpression of TNF-a causes abnormalities in CNS function, and the direct action of TNF-a in the pathogenesis of the disease was confirmed by peripheral administration of TNF-a Ab (Probert et aI. , 1995) .
To further clarify whether TNF-a is a cerebroprotec tive or deleterious cytokine in brain, a rat model of reper fusion brain injury after MeA occlusion was used (Kit taka et aI., 1996; Wang et aI., 1997) . This reperfusion model is characterized by significant formation of reac-tive oxygen species in the brain (Chan, 1996; Siesjo, 1992) . The TNF-a plasma activity and therapeutic ef fects of systemic administration of anti-TNF-a Ab were studied in relation to brain injury and CBF changes.
MATERIALS AND METHODS
The studies were performed using Sprague-Dawley rats weighing 260 to 300 g obtained from Charles River Breeders (Hollister, CA, U.S.A.). The animals were housed under diur nal light conditions with unlimited access to food and water.
All procedures were done in accordance with the Animal Care
Guidelines at the University of Southern California and ap proved by the National Institutes of Health.
Plasma levels of tumor necrosis factor-alpha
Plasma TNF-a levels were quantitated using the commer cially available rat specific enzyme-linked immunoassay kit (Genzyme Cambridge, MA, U.S.A.) in a group of seven ani mals subjected to I-hour MCA occlusion. Blood samples (300 ILL) were drawn from an indwelling PE-50 catheter placed in the right femoral vein at 30 and 60 minutes after initiation of MCA occlusion, then 30, 60, and 120 minutes and 24 hours after the initiation of reperfusion. The whole blood was centri fuged at 10,000 rpm for 10 minutes at 4°C, and plasma re moved and stored at -20°C until thawed for TNF-a level de tennination.
Focal ischemia studies
Rats were deprived of food 12 hours before surgery. Revers ible MCA occlusion was performed using an intraluminal thread technique (Zea Longa et aI., 1989) as modified in our laboratory (Kittaka, et aI., 1996) in control rats (n = 9) and rats treated with anti-TNF-a Ab (n = 6). The procedure involved initial anesthesia with metofane and maintenance with 50 mg/ kg of intraperitoneal pentobarbital. Atropine methyl nitrate (0.18 mg/kg intraperitoneally) was given as premedication to prevent airway obstruction by mucus formation. The animals were allowed to breath spontaneously. Rectal temperature was maintained at 37°C by a thermostatically regulated heating pad.
A PE-50 catheter was introduced into the right femoral artery for continuous monitoring of the MABP, as well as for repeated sampling of blood for serial measurements of Pao2, Paco2, pH (ABL 30 Acid-Base Analyzer, Radiometer, Copenhagen, Den mark), hematocrit, and blood glucose.
Briefly, the surgical technique was as follows: under the operating microscope, the right carotid complex was exposed through a ventral midline incision, and the external carotid artery and its branches ligated. Temporary ligatures were placed around the common carotid artery and internal carotid artery to prevent bleeding. Through a transverse incision in the artery, a 3-0 monofilament nylon suture with rounded tip was introduced into the external carotid artery lumen, and gently advanced 17.5 mm into the internal carotid artery to occlude the MCA at its origin from the Circle of Willis. After 1 hour of occlusion, the thread was pulled out, the external carotid artery permanently tied at the level of bifurcation, and the common carotid artery and internal carotid artery sutures removed to allow reperfusion.
In experimental animals, the effects of polyclonal rabbit anti mouse TNF-a neutralizing Ab (0.36 mg/kg) (Genzyme, Cam bridge, MA, U.S.A.) dissolved in nonpyrogenic sterile saline were studied in rats after intravenous injection through a pre viously placed indwelling femoral PE-50 catheter. Antibody was given 1 hour before occlusion of the MCA. Control animals had a similarly placed indwelling catheter and received only vehicle. This anti-mouse TNF-a neutralizing Ab binds well to rat TNF-a (Teti, et aI., 1993) . 
Blood flow and head temperature measurements

Motor neurologic behavioral score
Neurologic examination was performed after 24 hours of reperfusion, just before killing. Neurologic outcome was scored on a six-point scale (Kittaka, et aI., 1996) : 0, no neurologic deficit (normal); I (failure to extend left forepaw fully), mild focal neurologic deficit; 2 (circling to the left), moderate focal neurologic deficit; 3 (falling to the left), severe focal deficit; 4, rats did not walk spontaneously and had a depressed level of consciousness; 5, stroke-related death.
Measurement of volume of injury
The area of injury was delineated by incubation of unfixed 2-mm coronal brain slices in 2% triphenyltetrazolium chloride in 0.173 mo1!L sucrose and 50 mmollL K+ phosphate buffer (pH 7.4) for 20 minutes at 37°C, and then stored in 10% for malin. Serial coronal sections were displayed on a digitizing video screen using an imaging system from Jandel Scientific (San Rafael, CA, U.S.A.), and the areas of nonstaining tissue were determined in each section. The volume of injury was calculated by summing affected areas from each coronal sec tion and multiplying by the thickness of each section. The volumes of the control and lesioned hemispheres were calcu lated, and the amount of injury was expressed as a percentage of lesioned hemisphere and in absolute tenns (cubic millime ters). The total injury volume of gray matter corrected for edema and the edema volume was calculated by subtracting the volume of the normal gray matter in the control hemisphere from the volume of gray matter in the lesioned hemisphere (Swanson et aI., 1990) . The edema volume was calculated by subtracting the volume of the normal gray matter in the control hemisphere from the volume of gray matter in the lesioned hemisphere (Swanson et aI., 1990) . Measurements of the vol ume of injury were done separately for the pallium and stria tum. A coronal section from each brain was obtained at the level of the optic chiasm. Representations of the injury areas of individual sections from each animal in control group and the group treated with anti-TNF-a were superimposed to gain an impression of the topography and incidence of infarction. The boundary of infarction was redrawn for each rat on the corre sponding coronal section, and the following areas delineated:
the infarct area where all rats were affected 100%, the infarct area where 50% or more of rats were affected, and the infarct area where less than 50% of rats were affected.
Statistical analysis
Levels of TNF-a, physiologic variables, and infarction and edema volumes were compared between groups using a Stu dent's t test. A P value of less than 0.05 was considered sta tistically significant.
RESULTS
Plasma activity of tumor necrosis factor-alpha
The MCA occlusion caused rapid, significant, and transient increase in plasma TNF-a levels in comparison with sham-operated animals ( Fig. 1) , beginning as early as 30 minutes after the onset of occlusion (71 % of rats), with all animals showing increased levels by 1 hour. During reperfusion, high levels of TNF-a were main tained up to 2 hours into reperfusion, then normalized by 24 hours. Peak levels occurred at the onset of reperfusion for 57% of rats and 1 hour into reperfusion for the re maining 43%. The TNF-a levels in the MCA group var ied widely between animals (range 78 to 12,878 pg/mL) and are therefore expressed as logarithmic values to demonstrate the consistent trend found, despite indi vidual differences in magnitude. Sham-operated animals demonstrated no TNF-a activity, and no activity was seen before initiation of MCA occlusion. Despite wide variations of TNF-a levels in the MCA group, there was for each studied time point a statistically significant difference in comparison with sham-operated animals ( Fig. 1) .
Physiologic variables .
There were no significant statistical differences III MABP, Pao2, Paco2, pH, hematocrit, head and body temperature, and blood glucose between the control and anti-TNF-a Ab groups before MCA occlusion, during occlusion, and during reperfusion (Table 1) . No changes in head and body temperature were observed from Ab treatment during 1 hour before MCA occlusion, and all blood parameters during that period also were within normal limits (data not shown).
No significant differences in baseline tissue perfusion units were observed between control rats and those treated with anti-TNF-a Ab, indicating similar preocclu sion CBF values. Baseline CBF readings also were taken before TNF Ab administration, and there was no signifi cant difference with preocclusion values, indicating that the Ab did not influence the CBF under basal conditions. During MCA occlusion, the reductions in CBF in the ischemic core (point A) were comparable among the groups: 15% to 16% (P < 0.001, control MCA group) and 12% to 14% (P < 0.001, MCA group treated with anti-TNF-a Ab) of baseline values (Fig. 2) . In the pe riphery of the ischemic core (points B and D), the re spective reductions in CBF were 35% to 37% (P < 0.001, control MCA group) and 32% to 35% (P < 0.001, MCA group treated with anti-TNF-a Ab) of baseline values. During the first 30 minutes of reperfusion, the trend to ward CBF restoration was comparable between the two groups: in the core, the average values were 46% versus 43% in control and MCA group treated with anti-TNF-a Ab, whereas in the periphery of the ischemic core the values ranged from 75% (point B) to 77% (point D) in the control group versus 72% (point B) to 75% (point D) in the MCA group treated with anti-TNF-a Ab ( Fig. 1 ; Table 2 ). However, during 30 to 60 minutes of reperfu sion, the recovery of CBF was significantly improved in the MCA group treated with anti-TNF-a Ab; in the core, the average values were 71 % (MCA group treated with anti-TNF-a Ab) versus 55% (control group) ( Fig. 1 ; Table 2 ), representing a 30% increase in flow. Relatively modest but significant effects of Ab on CBF during reperfusion were observed in both studied points in the periphery of ischemic core. The lack of more pronounced effect of Ab in these regions could be explained by sig nificant spontaneous recovery of CBF even without Ab intervention ( Fig. 2; Table 2 ).
Motor neurologic behavioral score
After 24 hours of reperfusion, the control group had a mean neurologic score of 0.56 ± 0.17, which was re duced by nearly twofold (0.33 ± 0.21) by treatment with Glucose, mmolfL 4. 4 ± 0. 5 4.6 ± 0. 6 4. 3 ± 0. 4 4.6 ± 0. 5 4. 2 ± 0. 4 4.4 ± 0.6
Values are mean ± SD, n = 9 for control MCA group, n = 6 for the MCA group treated with anti-TNF-a Ab. MABP, mean arterial blood pressure;
T, temporalis muscle temperature. Preocclusion data were collected 10 minutes before MCA occlusion. For MCA occlusion, data at 10, 30 and 60 minutes (except for T) were pooled because there were no significant differences between time points. Likewise, reperfusion data at 10 and 60 minutes (except for T) were pooled. Data for T were collected 10 minutes before, 60 minutes after MCA occlusion and 60 minutes after reperfusion. There were no significant differences between the groups for all variables listed above.
anti-TNF-a Ab. The Kruskal-Wallis test, however, did not reach the level of significance. Possible reason for this is that neither of the animals in either group had developed a score greater than I. Thus, with this method, the scores were limited to only a narrow range of either o or I (and no values in between), which significantly lowered the sensitivity of the neurologic scale for statis- r---Occlusion --' � I (--Reperfusion ----1
Time (min)
tical comparisons and precluded discrete neurologic changes between the groups to be detected.
Neuropathology
Rats treated with anti-TNF-a Ab had a significant reduction in the volume of brain injury compared with control rats of 71 % (P < 0.015) in the cortical region, and 100.0 ± 1.30 100.0 ± 1.70* 102.8 ± 1.7 103. ± 0.4* 102.4 ± 2.5 102.0 ± 0.5* D (Periphery of ischemic core) 100.0 ± 0.80 100.0 ± 1.00* 76.9 ± 9.2 75.0 ± 8.7* 86.2 ± 0.6 93.5 ± 0.7t
Values are mean ± SD. The number of CBF measurements during each studied period of time was 6 to 12 for the mean values listed in the table.
Values are expressed as a percentage of baseline preocclusion CBF values determined within the 30-minute period before MCA occlusion in either group. CBF measurements were obtained on 3 animals in control MCA group and Anti-TNF-a Ab treated MCA group. Student's I-test was used for comparisons between the two groups; *non-significant for preocclusion CBF values and for CBF values during 0 to 30 minutes of reperfusion in
Anti-TNF-a Ab versus control group; tP < 0.05 for CBF values during 30 to 60 minutes of reperfusion in Anti-TNF-a Ab versus control group. 58% (P < 0.007) in the subcortical region (Table 3) . Edema volume was not significantly different between the groups. The total volume of injury of gray matter (corrected for edema) was significantly decreased by 66% in the Ab-treated group relative to control rats (P < 0.001). The percent volume of the lesioned hemisphere involved in the Ab-treated group was 59% smaller than the control group (P < 0.0001). Total area of brain injury determined at the level of the optic chiasm (anterior co ronal block) and expressed as a percentage of the coronal sectional area is depicted in Fig. 3 . Figure 3 illustrates that 100% of control and Ab-treated rats had injury in the lateral striatum, 50% or more exhibited changes in the medial striatum and lateral cortex, and less than 50% showed changes in the dorsolateral cortex with a signifi cant reduction of area in each region for the Ab-treated animals.
DISCUSSION
The current study demonstrates that TNF-a is rapidly and transiently released into circulation during focal ischemia and early reperfusion, and that circulating anti TNF-a Ab protects the brain from reperfusion injury. Rapid TNF-a synthesis (within 30 minutes) has been shown in brain after permanent MCA occlusion in nor mal and spontaneously hypertensive rats (Liu et aI. , 1994; Buttini et aI., 1996) and in gerbils after transient global cerebral ischemia (Saito et aI., 1996) . Increased plasma TNF-a activity has been shown 4 hours after permanent MeA occlusion in spontaneously hyperten sive rats (Dawson et aI., 1996) . It has been suggested that TNF-a could exacerbate eNS injury by several mecha nisms (Feurstein et aI., 1994) . Our study supports the contention that TNF-a is a deleterious cytokine in stroke and plays a major role in the pathophysiologic mecha nism of cerebral ischemia. Recent studies demonstrated that inhibition of TNF-a by topical, intraperitoneal, or intravenous administration of TNFbp resulted in 10% to 26% reduction of total brain injury after permanent MeA occlusion in mice (Na washiro et aI., 1997), whereas better results were ob tained in spontaneously hypertensive rats (Dawson et aI., (A) (8) D<50% _�50% _100% FIG. 3. Incidence and topography of the infarction at the level of the optic chiasm during' reversible MeA occlusion in control rats (A) (n = 9) and rats treated with anti-TNF -a Ab (8) (n = 6).
1996). The degree of neuroprotection with circulating anti-TNF-a Ab in the current model was 58% for the striatum, 71 % in the cortex, and 66% for the total volume of injury in gray matter, which was much higher than the protection seen in the studies with TNFbp. The reduction in brain injury that we have shown also is more substan tial than that seen after other neuroprotective agents in cluding the noncompetitive N-methyl-D-aspartate an tagonist MK80, the immunosuppressive drug FK506 (Sharkey and Butcher, 1994) , the voltage-sensitive cal cium channel blockers (Kittaka et aI. , 1997) , or U-74006F, which is an inhibitor of lipid peroxidation (Hall et aI., 1988) . However, consider that most neuroprotec tive agents (e. g., MK-801) are more efficacious against transient rather than permanent MCA occlusion, and that differences in ischemia models (permanent versus tran sient) and species also could play a role. Thus, to make a direct comparison between TNF Ab and TNFbp, it would be necessary to construct parallel dose-response curves using the same model of ischemia and the same species or strain of animal. A preliminary report indicat ing that direct injection of anti-TNF-a Ab into the isch emic penumbra reduces infarction volume by 82% (Meistrell et aI., 1997) is consistent with the current find ings.
Other studies have demonstrated that systemic admin istration of anti-TNF-a Ab resulted in significant neu roprotection in transgenic mice overexpressing TNF-a (Probert et aI. , 1995) , whereas a combined systemic and intraventricular administration of anti-TNF-a prevented albumin leakage into the CSF in a meningitis model in rats (Kim et aI., 1992 ). An international, multicenter, placebo-controlled trial has demonstrated that intrave nous administration of monoclonal anti-TNF-a Ab is a safe and feasible therapeutic modality in the treatment of patients with sepsis (Cohen and Carlet, 1996) . Thus, it is possible that the inhibition of TNF-a by intravenous anti-TNF-a Ab also may be effective in the treatment of stroke patients by ameliorating the consequences of sev eral pathophysiologic processes triggered by TNF-a (Feurstein et aI., 1994) .
It is not known why in the current study the anti TNF-a Ab treatment completely spared the ventral por tion of the cortex. In the current MCA model (Kittaka et aI., 1996; Wang et aI. , 1997; Kittaka et aI., 1997) , how ever, the infarct was located in all animals in the lateral striatum, and in more than 50% of animals in the lateral cortex, whereas only in less than 50% of animals the infarction extended to the ventromedial and dorsolateral cortex. The spatial localization of infarct in the animals treated with anti-TNF-a Ab possibly reflects regional dependent neuroprotection that could be related to dif ferential regional levels of TNF-a production by brain in response to focal ischemic insult and reperfusion. This hypothesis currently is under study in our laboratory.
Associated with the decreased volume of brain injury after TNF-a inhibition in the current study was a signifi cant increase in the restoration of CBF during reperfu sion and in particular within the ischemic core. It has been shown that TNF-a affects the release of the vaso active agents endothelin-l and nitric oxide from cerebral endothelial and smooth muscle cells (Estrada et aI., 1995) and causes dose-dependent pial vasoconstriction and blood-brain barrier breakdown (Megyeri et aI. , 1992) . This cytokine promotes thrombus formation and procoagulant transformation of the vascular endothelium (Nawroth and Stern, 1986; Pober, 1988) , and promotes leukocyte recruitment, infiltration, and adhesion to cere bral capillaries, resulting in increased accumulation and thrombosis (Feurstein et aI., 1994) . Direct cytotoxic ef fects on glial and cerebral endothelium and decreased CBF after administration of TNF-a also have been shown (Feurstein et aI., 1994; Tureen, 1995; Estrada et aI., 1995) . Thus, although TNF-a may not be directly neurotoxic in vitro (Barger at aI. , 1995; Barone et aI., 1997) , the inhibition of TNF-a by intravenous anti TNF-a Ab may ameliorate the consequences of several pathophysiologic vascular mechanisms active in cerebral ischemia. Further study of the specific effects of TNF-a are likely to elucidate the precise mechanisms involved.
Finally, it is intriguing whether anti-TNF-a Ab or TNFbp could be used successfully in post-stroke or post head trauma treatments to block effects of TNF-a. Al though Current and previous studies have clearly estab lished TNF-a as a major deleterious cytokine in stroke, they still have not given enough focus to possible thera peutic advantages of TNF-a blockade. One study sug gests that administering TNFbp within 30 minutes before and after MCA occlusion was similarly effective in re ducing focal ischemic injury, but in most studies TNFbp was given either immediately after closed head injury (Shohami et aI., 1996) or MCA occlusion (Nawashiro et aI., 1997) , or TNFbp and TNF-a Ab were administered using protocols that involves repetitive intracerebroven tricular injections before and after MCA occlusion (Bar one et aI., 1997). Future studies should evaluate dose related effects of TNF-a blockade at different time in tervals after an ischemic insult or head injury to determine the potential of this approach for post-stroke and post-head trauma treatments.
